864754-18-7

Basic information

• Product Name: 1-(2-MORPHOLINOETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER
• Synonyms: 1-(2-MORPHOLINOETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER;4-(2-[4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRAZOL-1-YL]-ETHYL)-MORPHOLINE;1-(2-MORPHOLINOETHYL)-1H-PYRAZOL-4-BORONIC ACID PINACOL ESTER;4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethyl)morpholine;1-[2-(Morpholin-4-yl)ethyl]-1H-pyrazole-4-boronic acid, pinacol ester;Morpholine, 4-[2-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]ethyl]-;1-(2-Morpholinoethyl)-1H-pyrazole-4-boronic acid;4-{2-[4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]ethyl}Morpholine
• CAS NO: 864754-18-7
• Molecular Formula: C₁₅H₂₆BN₃O₃
• Molecular Weight: 307.2
• Product Categories: Boronate Esters;Boronic Acids and Derivatives;Chemical Synthesis;Heteroaryl Boronate Esters;Organometallic Reagents
• Mol File: 864754-18-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 89-94℃
• Boiling Point: 440.6°C at 760 mmHg
• Flash Point: 220.3°C
• Appearance: /
• Density: 1.15±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 5.81E-08mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.71±0.10(Predicted)
• CAS DataBase Reference: 1-(2-MORPHOLINOETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-MORPHOLINOETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER(864754-18-7)
• EPA Substance Registry System: 1-(2-MORPHOLINOETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER(864754-18-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36-38
• Safety Statements: 26
• WGK Germany: 2
• Hazardous Substances Data: 864754-18-7(Hazardous Substances Data)

Usage

General Description

The chemical "1-(2-MORPHOLINOETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER" is a boronic acid compound that contains a pyrazole ring and a morpholinoethyl group. It is commonly used in organic synthesis as a reagent for the introduction of boronic acid functionality into organic molecules. The pinacol ester group on the molecule contributes to its stability and solubility in organic solvents. 1-(2-MORPHOLINOETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER has applications in the pharmaceutical and agrochemical industries, as well as in the development of new materials for electronic and optical devices. Additionally, it is a valuable building block for the synthesis of various biologically active molecules.

InChI:InChI=1/C15H26BN3O3/c1-14(2)15(3,4)22-16(21-14)13-11-17-19(12-13)6-5-18-7-9-20-10-8-18/h11-12H,5-10H2,1-4H3

Upstream product

• 89583-07-3 N-(2-bromoethyl)morpholine 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 73183-34-3 bis(pinacol)diborane 
• 3240-94-6 N-(2-chlorethyl)morpholine 
• 42802-94-8 4-(2-bromoethyl)morpholine hydrobromide 

Downstream Products

• 1032900-22-3 N₂-{2-isopropoxy-4-methyl-5-[1-(2-morpholin-4-yl-ethyl)-1H-pyrazol-4-yl]-phenyl}-5-methyl-N₄-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine 
• 1285517-43-2 methyl 2-{[(4-fluorophenyl)methyl]oxy}-5-{1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl}benzoate 
• 1161737-38-7 (3-{5-[1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-yl]pyrimidin-2-yl}-phenyl)methanol 
• 1352152-61-4 (S)-tert-butyl 1-(1-amino-3-(4-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)phenyl)-1-oxopropan-2-ylcarbamoyl)cyclohexylcarbamate 
• 1403254-62-5 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-3-(methyl(tetrahydro-2H-pyran-4-yl)amino)-5-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)benzamide 
• 1403259-18-6 tert-butyl 4-((3-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-2-methyl-5-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)phenyl)(methyl)amino)piperidine-1-carboxylate 
• 1403254-90-9 3-(((1R,4R)-4-acetamidocyclohexyl)(methyl)amino)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-5-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)benzamide 
• 1403257-86-2 tert-butyl(((1S,4S)-4-(3-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-2-methyl-5-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)phenyl)(methyl)amino)cyclohexyl)carbamate 
• 1403257-94-2 tert-butyl ((1R,4R)-4-((3-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-2-methyl-5-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)phenyl)(methyl)amino)cyclohexyl)carbamate 
• 1430724-69-8 N-(2',5'-difluoro-5-(5-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)-1H-benzo[d]-imidazol-1-yl)biphenyl-3-yl)acetamide 

Relevant articles and documents

Design, synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors

The abnormal activation of JAK2 kinase is closely related to the occurrence and progression of myeloproliferative neoplasms (MPNs). At present, there is still an obvious unmet medical need for selective JAK2 inhibitors in clinic. In this paper, a class of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors was obtained by combining drug design, synthesis and structure-activity relationship studies based on the previously identified lead Crizotinib. Among them, 21b exhibited high inhibitory activity against JAK2 with an IC50 of 9 9 nmol/L, moreover, it showed 276- and 184-fold selectivity over JAK1 and JAK3, respectively. Besides, 21b had a significant antiproliferative activity against HEL cells, and also inhibited the phosphorylation of JAK2 and its down-stream signaling pathway. These results indicated that 2-aminopyridine compound 21b had the potential to be developed as a selective JAK2 inhibitor for further study.

N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

PYRAZOLOPYRIMIDINE DERIVATIVES

The present invention covers Pyrazolopyrimidine compounds of general formula (I), in which n, o, X, Y, R, Q, R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds u